Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy

W Boisseau; M Touat; G Berzero; J Savatovsky; A Marabelle; V Touitou; D Ricard; G Malouf; D Psimaras

doi:10.1016/j.ejca.2017.05.036

Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy

Eur J Cancer. 2017 Sep:83:28-31. doi: 10.1016/j.ejca.2017.05.036. Epub 2017 Jul 12.

Authors

W Boisseau¹, M Touat², G Berzero³, J Savatovsky⁴, A Marabelle⁵, V Touitou⁶, D Ricard⁷, G Malouf⁸, D Psimaras⁹

Affiliations

¹ OncoNeuroTox Group: Center for Patients with Neurological Complications of Oncologic Treatments, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix et Hôpital Percy, Paris, France; Department of Neurology 2 (Mazarin), Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Assistance Publique Hôpitaux de Paris (APHP), Paris, France.
² OncoNeuroTox Group: Center for Patients with Neurological Complications of Oncologic Treatments, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix et Hôpital Percy, Paris, France; Department of Neurology 2 (Mazarin), Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Assistance Publique Hôpitaux de Paris (APHP), Paris, France; UMR975 INSERM-UPMC, GH Pitié- Salpêtrière, Paris, France.
³ Department of Neurology 2 (Mazarin), Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Assistance Publique Hôpitaux de Paris (APHP), Paris, France; Neuroscience Consortium, Università di Pavia Monza Policlinico and Pavia Mondino, Italy.
⁴ Department of Neuroradiology, Fondation Rothschild Hospital, Paris, France.
⁵ INSERM U1015, Gustave Roussy, Villejuif, France.
⁶ Department of Ophtalmology, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Assistance Publique Hôpitaux de Paris (APHP), Paris, France.
⁷ OncoNeuroTox Group: Center for Patients with Neurological Complications of Oncologic Treatments, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix et Hôpital Percy, Paris, France; Department of Neurology, Military Training Hospital Percy, Service de Santé des Armées, Paris, France; Military Health Service Academy of Val-de-Grâce, Service de Santé des Armées, Paris, France.
⁸ Department of Oncology, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Assistance Publique Hôpitaux de Paris (APHP), Paris, France.
⁹ OncoNeuroTox Group: Center for Patients with Neurological Complications of Oncologic Treatments, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix et Hôpital Percy, Paris, France; Department of Neurology 2 (Mazarin), Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Assistance Publique Hôpitaux de Paris (APHP), Paris, France; UMR975 INSERM-UPMC, GH Pitié- Salpêtrière, Paris, France. Electronic address: [email protected].

PMID: 28710954
DOI: 10.1016/j.ejca.2017.05.036

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / pathology
Drug Substitution
Female
Humans
Ipilimumab / adverse effects*
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / pathology
Meningitis / chemically induced*
Meningitis / complications
Neoplasm Metastasis
Nivolumab
Optic Nerve Diseases / chemically induced*
Optic Nerve Diseases / complications
Radiculopathy / chemically induced*
Radiculopathy / complications

Substances

Antibodies, Monoclonal
Ipilimumab
Nivolumab